<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
	article-type="research-article">
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">J Exp Med</journal-id>
			<journal-title>The Journal of Experimental Medicine</journal-title>
			<issn pub-type="ppub">0022-1007</issn>
			<issn pub-type="epub">1540-9538</issn>
			<publisher>
				<publisher-name>The Rockefeller University Press</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="pmc">2193563</article-id>
			<article-id pub-id-type="publisher-id">020408</article-id>
			<article-id pub-id-type="doi">10.1084/jem.20020408</article-id>
			<article-id pub-id-type="pmid">12070292</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Brief Definitive Report</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Protein Kinase C &#x003b2; Controls Nuclear Factor
					&#x003ba;B Activation in B Cells Through Selective Regulation of
					the I&#x003ba;B Kinase &#x003b1;</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<name>
						<surname>Saijo</surname>
						<given-names>Kaoru</given-names>
					</name>
					<xref ref-type="aff" rid="aff1">1</xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Mecklenbr&#x000e4;uker</surname>
						<given-names>Ingrid</given-names>
					</name>
					<xref ref-type="aff" rid="aff1">1</xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Santana</surname>
						<given-names>Angela</given-names>
					</name>
					<xref ref-type="aff" rid="aff1">1</xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Leitger</surname>
						<given-names>Michael</given-names>
					</name>
					<xref ref-type="aff" rid="aff2">2</xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Schmedt</surname>
						<given-names>Christian</given-names>
					</name>
					<xref ref-type="aff" rid="aff1">1</xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Tarakhovsky</surname>
						<given-names>Alexander</given-names>
					</name>
					<xref ref-type="aff" rid="aff1">1</xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>1</label>
				Laboratory of Lymphocyte Signaling, Rockefeller University, New
				York, NY 10021
			</aff>
			<aff id="aff2">
				<label>2</label>
				Max-Plank-Institut f&#x000fc;r Experimentelle Endokrinologie,
				Fedor-Lynen-Str. 7, 30625 Hannover, Germany
			</aff>
			<author-notes>
				<fn>
					<p>
						Address correspondence to Kaoru Saijo or Alexander Tarakhovsky,
						Laboratory of Lymphocyte Signaling, Rockefeller University, 1230
						York Ave., New York, NY 10021. Phone: 212-327-8265 (K. Saijo) or
						8256 (A. Tarakhovsky)&#x0003b; Fax: 212-327-8258&#x0003b; E-mail:
						<email>saijok@mail.rockefeller.edu</email>
						or
						<email>tarakho@mail.rockefeller.edu</email>
					</p>
				</fn>
			</author-notes>
			<pub-date pub-type="ppub">
				<day>17</day>
				<month>6</month>
				<year>2002</year>
			</pub-date>
			<volume>195</volume>
			<issue>12</issue>
			<fpage>1647</fpage>
			<lpage>1652</lpage>
			<history>
				<date date-type="received">
					<day>13</day>
					<month>3</month>
					<year>2002</year>
				</date>
				<date date-type="rev-recd">
					<day>23</day>
					<month>4</month>
					<year>2002</year>
				</date>
				<date date-type="accepted">
					<day>9</day>
					<month>5</month>
					<year>2002</year>
				</date>
			</history>
			<permissions>
				<copyright-statement>Copyright &#x000a9; 2002, The Rockefeller
					University Press</copyright-statement>
			</permissions>
			<abstract>
				<p>Activation of the nuclear factor (NF)-&#x003ba;B transcription
					complex by signals derived from the surface expressed B cell
					antigen receptor controls B cell development, survival, and
					antigenic responses. Activation of NF-&#x003ba;B is critically
					dependent on serine phosphorylation of the I&#x003ba;B protein by
					the multi-component I&#x003ba;B kinase (IKK) containing two
					catalytic subunits (IKK&#x003b1; and IKK&#x003b2;) and one
					regulatory subunit (IKK&#x003b3;). Using mice deficient for protein
					kinase C &#x003b2; (PKC&#x003b2;) we show an essential role of
					PKC&#x003b2; in the phosphorylation of IKK&#x003b1; and the
					subsequent activation of NF-&#x003ba;B in B cells. Defective
					IKK&#x003b1; phosphorylation correlates with impaired B cell
					antigen receptor&#x02013;mediated induction of the pro-survival
					protein Bcl-xL. Lack of IKK&#x003b1; phosphorylation and defective
					NF-&#x003ba;B induction in the absence of PKC&#x003b2; explains the
					similarity in immunodeficiencies caused by PKC&#x003b2; or
					IKK&#x003b1; ablation in B cells. Furthermore, the well established
					functional cooperation between the protein tyrosine kinase Bruton's
					tyrosine kinase (Btk), which regulates the activity of
					NF-&#x003ba;B and PKC&#x003b2;, suggests PKC&#x003b2; as a likely
					serine/threonine kinase component of the Btk-dependent
					NF-&#x003ba;B activating signal transduction chain downstream of
					the BCR.</p>
			</abstract>
			<kwd-group>
				<kwd>B cell survival</kwd>
				<kwd>B cell receptor</kwd>
				<kwd>signal transduction</kwd>
				<kwd>I&#x003ba;B kinase complex</kwd>
				<kwd>Btk</kwd>
			</kwd-group>
		</article-meta>
	</front>
	<body>
		<sec>
			<title>Introduction</title>
			<p>
				Efficient B cell immunity requires mechanisms that guarantee the
				representation of a diverse immunoglobulin repertoire within the
				peripheral B cell pool (
				<xref ref-type="bibr" rid="bib1">1</xref>
				). A key feature of peripheral B cells in this context is their
				ability to persist in the absence of antigenic stimulation. The
				relatively long life of mature naive B cells in peripheral lymphoid
				organs of mice and man increases the likelihood for an individual B
				cell to encounter an antigen and initiate an effective humoral
				immune response (
				<xref ref-type="bibr" rid="bib2">2</xref>
				). Conversely, reduced peripheral B cell survival is frequently
				associated with naturally occurring or genetically engineered
				immunodeficiencies (
				<xref ref-type="bibr" rid="bib3">3</xref>
				,
				<xref ref-type="bibr" rid="bib4">4</xref>
				).
			</p>
			<p>
				Survival of peripheral B cells is critically dependent on the
				surface expression of the B cell antigen receptor (BCR) and its
				ability to generate a signal. Ablation of surface expressed BCR on
				peripheral B cells by Cre recombinase-mediated modification of the
				Ig locus or inducible inactivation of Syk protein kinase gene lead
				to rapid B cell death (
				<xref ref-type="bibr" rid="bib5">5</xref>
				&#x0003b; and unpublished data). These observations suggest a
				BCR-dependent signaling cascade responsible for B cell survival in
				the absence of antigenic stimulation. Furthermore, reduction in the
				expression level of Bcl-2 protein after the BCR ablation and the
				rescue from apoptosis of BCR-deficient B cells by Bcl-2
				overexpression point to the existence of a signaling axis connecting
				the BCR and transcription of anti-apoptotic Bcl-2 family of proteins
				(
				<xref ref-type="bibr" rid="bib5">5</xref>
				). A likely link between the BCR and expression of the
				anti-apoptotic proteins is suggested by the ability of the BCR to
				trigger the activation of nuclear factor (NF)-&#x003ba;B, which is
				known to control the expression of Bcl-2 and Bcl-xL (
				<xref ref-type="bibr" rid="bib6">6</xref>
				). Successful activation of NF-&#x003ba;B and hence transcription of
				the NF-&#x003ba;B&#x02013;dependent genes by various ligands
				requires the phosphorylation of the inhibitory protein I&#x003ba;B.
				Unphosphorylated I&#x003ba;B is bound to the complex of the
				transcription activating Rel-subunits and retains these within the
				cytoplasm. Upon cellular activation, I&#x003ba;B is phosphorylated
				on serine residues by the multicomponent I&#x003ba;B kinase (IKK)
				containing two catalytic subunits (IKK&#x003b1; and IKK&#x003b2;)
				and one regulatory subunit (IKK&#x003b3;). Phosphorylation of
				I&#x003ba;B targets it for ubiquitination and subsequent degradation
				by the proteasome (
				<xref ref-type="bibr" rid="bib7">7</xref>
				,
				<xref ref-type="bibr" rid="bib8">8</xref>
				).
			</p>
			<p>
				Recent studies demonstrated that phosphorylation of
				I&#x003ba;B&#x003b1; downstream of BCR triggering is regulated by
				the Bruton's tyrosine kinase (Btk&#x0003b; references
				<xref ref-type="bibr" rid="bib9">9</xref>
				and
				<xref ref-type="bibr" rid="bib10">10</xref>
				). Mutation of Btk results in X-linked agammaglobulinemia (XLA) in
				humans and X-linked immunodeficiency (Xid) in mice (
				<xref ref-type="bibr" rid="bib11">11</xref>
				). BCR cross-linking induces I&#x003ba;B&#x003b1; phosphorylation in
				wild-type B cells, whereas Btk-deficient B cells or Xid B cells are
				unable to support I&#x003ba;B&#x003b1; phosphorylation and efficient
				activation of NF-&#x003ba;B. Combined with the short life-span and
				inefficient Bcl-xL induction of Btk-deficient/Xid B cells, these
				data support an important role of Btk-mediated NF-&#x003ba;B
				activation in BCR-dependent B cell survival (
				<xref ref-type="bibr" rid="bib9">9</xref>
				,
				<xref ref-type="bibr" rid="bib10">10</xref>
				,
				<xref ref-type="bibr" rid="bib12">12</xref>
				).
			</p>
			<p>
				The substrate specificity of Btk as a tyrosine kinase precludes its
				direct involvement in the phosphorylation of IKKs or I&#x003ba;Bs on
				serine residues. This, in turn, implies the existence of a
				Btk-dependent serine kinase involved in the regulation of IKK
				activity, I&#x003ba;B phosphorylation, and NF-&#x003ba;B activation
				(
				<xref ref-type="bibr" rid="bib9">9</xref>
				,
				<xref ref-type="bibr" rid="bib10">10</xref>
				).
			</p>
			<p>
				Recently, a functional link between Btk and the Ca
				<sup>2+</sup>
				/diacylglycerol (DAG)-dependent serine/threonine protein kinase C
				&#x003b2; (PKC&#x003b2;) was demonstrated. B cells of mice deficient
				for PKC&#x003b2; display a signaling phenotype similar to Xid B
				cells (
				<xref ref-type="bibr" rid="bib13">13</xref>
				&#x02013;
				<xref ref-type="bibr" rid="bib15">15</xref>
				). We therefore hypothesized that PKC&#x003b2; may be involved in
				the Btk-mediated NF-&#x003ba;B activation in B cells.
			</p>
			<p>Here we demonstrate that PKC&#x003b2; selectively controls
				phosphorylation of IKK&#x003b1; in mature B cells and is required
				for the efficient BCR-induced I&#x003ba;B&#x003b1; phosphorylation,
				degradation, and subsequent NF-&#x003ba;B induction. Furthermore,
				impaired phosphorylation of IKK&#x003b1; and compromised activation
				of NF-&#x003ba;B correlate with defective BCR-mediated induction of
				Bcl-xL in B cells, thus providing a mechanistic explanation for the
				reduced life-span of PKC&#x003b2;-deficient B cells.</p>
		</sec>
		<sec sec-type="materials|methods">
			<title>Materials and Methods</title>
			<sec>
				<title>Mice.</title>
				<p>
					PKC&#x003b2;
					<sup>&#x02212;/&#x02212;</sup>
					mice on C57BL/6 or 129/Sv genetic background were used for analysis
					(
					<xref ref-type="bibr" rid="bib13">13</xref>
					). Mice were kept in the animal facility of the Institute for
					Genetics at the University of Cologne or in the SPF facility of the
					Laboratory Animal Research Center at The Rockefeller University
					following the university guide lines. Wild-type C57BL/6 or 129/Sv
					mice were purchased from The Jackson Laboratory or Charles River
					Laboratories, respectively.
				</p>
			</sec>
			<sec>
				<title>B Cell Proliferation.</title>
				<p>
					Splenic B cells of &#x0003e;95% purity were isolated as described
					previously (
					<xref ref-type="bibr" rid="bib16">16</xref>
					). Splenic B cells were stimulated in vitro with 1.2 &#x003bc;g/ml
					goat anti&#x02013;mouse IgM F(ab&#x02032;)
					<sub>2</sub>
					(Jackson ImmunoResearch Laboratories), 7.5 &#x003bc;g/ml anti-CD38
					(
					<xref ref-type="bibr" rid="bib17">17</xref>
					), or 5.25 &#x003bc;g/ml anti-RP105 (
					<xref ref-type="bibr" rid="bib18">18</xref>
					) alone or in combination with 25 U/ml recombinant mouse IL-4
					(Genzyme) as described previously (
					<xref ref-type="bibr" rid="bib16">16</xref>
					). Labeling of cells with 5-(and 6-)-carboxyfluorescein diacetate,
					succinimidyl ester (CFDA-SE&#x0003b; Molecular Probes) for
					measurement of the proliferative responses was performed as
					described (
					<xref ref-type="bibr" rid="bib19">19</xref>
					). The decline in CFSE fluorescence as measure of B cell
					proliferation was determined by FACS
					<sup>&#x000ae;</sup>
					analysis.
				</p>
			</sec>
			<sec>
				<title>Cell Survival Assay.</title>
				<p>
					Purified splenic B cells were cultured in the absence or presence
					of 25 U/ml recombinant mouse IL-4 (Genzyme) for various times.
					Cells were washed once with ice-cold Annexin V binding buffer (10
					mM Hepes, pH 7.5, 140 mM NaCl, 5 mM KCl, 1 mM MgCl
					<sub>2</sub>
					, 1.8 mM CaCl
					<sub>2</sub>
					) and cell pellets were stained with Annexin V (Roche) and
					7-aminoactinomycin D (7AAD&#x0003b; Sigma-Aldrich) as described (
					<xref ref-type="bibr" rid="bib5">5</xref>
					).
				</p>
			</sec>
			<sec>
				<title>Western Blotting Analysis and EMSA.</title>
				<p>
					The expression level of Bcl-2 and Bcl-xL proteins were analyzed by
					Western blotting. Splenic B cells were purified as described
					previously (
					<xref ref-type="bibr" rid="bib16">16</xref>
					). 2 &#x000d7; 10
					<sup>6</sup>
					purified B cells were cultured with 10 &#x003bc;g/ml F(ab&#x02032;)
					<sub>2</sub>
					fragment goat anti-IgM (Jackson ImmunoResearch Laboratories) for
					indicated time. Cells were harvested and lysed by 1% NP-40
					containing buffer as described previously (
					<xref ref-type="bibr" rid="bib16">16</xref>
					). Anti-Bcl-2 (Neomarkers) and anti-Bcl-xL (Cell Signaling
					Technology) were used for this analysis. The loading of the protein
					was controlled by Western blotting of anti-&#x003b1;-Actin
					(Oncogene Research Products).
				</p>
				<p>
					For the analysis of Rel family protein expression, the protein
					lysate of purified splenic B cells from PKC&#x003b2;
					<sup>&#x02212;/&#x02212;</sup>
					and control mice were analyzed by Western blotting with antibodies
					against RelA, RelB, c-Rel, and p52 (Santa Cruz Biotechnology,
					Inc.). To analyze the IKK&#x003b1;/IKK&#x003b2;/IKK&#x003b3;
					complex, purified splenic B cells were lysed 1% CHAPS containing
					buffer. After the centrifugation and removal of the insoluble
					fraction, the protein lysates were precleared by rabbit Ig and
					protein A-sepharose. The IKK complex was immunoprecipitated with
					anti-IKK&#x003b1; antibody (Cell Signaling Technology) or control
					rabbit Ig followed by the incubation with protein
					A&#x02013;sepharose. Sepharose beads were washed three times with
					lysis buffer and subjected to SDS-PAGE and transferred onto PVDF
					membrane. The membrane was incubated with anti-IKK&#x003b1;
					(Upstate Biotechnology), anti-IKK&#x003b2; (Upstate Biotechnology),
					or anti-IKK&#x003b3; antibodies (Santa Cruz Biotechnology, Inc.).
				</p>
				<p>
					NF-&#x003ba;B activation was studied after the stimulation with 20
					&#x003bc;g/ml goat anti&#x02013;mouse IgM F(ab&#x02032;)
					<sub>2</sub>
					(Jackson ImmunoResearch Laboratories) or 10 &#x003bc;g/ml anti-CD40
					(3/23&#x0003b; BD PharMingen) using cytoplasmic and nuclear
					extracts prepared as described (
					<xref ref-type="bibr" rid="bib19">19</xref>
					). Degradation and phosphorylation of I&#x003ba;B&#x003b1; protein
					were measured by Western blotting with anti-I&#x003ba;B&#x003b1;
					antibody (Santa Cruz Biotechnology, Inc.) and anti-phospho
					I&#x003ba;B&#x003b1; (Ser32&#x0003b; Cell Signaling Technology).
					The phosphorylation of IKK&#x003b1; and IKK&#x003b2; was analyzed
					by the antibody against phospho-specific form of IKK&#x003b1;
					(Ser180) and IKK&#x003b2; (Ser181&#x0003b; Cell Signaling
					Technology). For the loading control, the membranes were stripped
					and reprobed with anti-IKK&#x003b1; and anti-IKK&#x003b2;
					antibodies (Upstate Biotechnology). DNA-binding activity of
					NF-&#x003ba;B was analyzed by electrophoretic mobility shift assay
					(EMSA) as described (
					<xref ref-type="bibr" rid="bib19">19</xref>
					). For the supershift, antibodies against p50, RelA and c-Rel
					(Santa Cruz Biotechnology, Inc.) were added before the binding
					reaction with DNA. A mutant oligonucleotide was used to test the
					specificity of DNA binding. The protein loading was determined by
					Oct-1 EMSA. All quantifications were done with NIH image software.
				</p>
			</sec>
		</sec>
		<sec>
			<title>Results and Discussion</title>
			<p>
				B cells deficient for Btk or expressing a mutant form of the Btk
				protein are characterized by drastically reduced life-span in vitro
				and in vivo (
				<xref ref-type="bibr" rid="bib12">12</xref>
				). Similar properties are characteristic for PKC&#x003b2;-deficient
				B cells. Incubation of ex vivo isolated splenic
				PKC&#x003b2;-deficient B cells in vitro in the absence of
				exogenously added agonists of B cell survival is accompanied by a
				rapid decline of cell viability (
				<xref rid="fig1" ref-type="fig">Fig. 1</xref>
				A). Similar to B cells with impaired Btk function, the
				PKC&#x003b2;-deficient B cells are characterized by drastically
				decreased proliferative responses to the antibody-mediated
				cross-linking of BCR, or to the polyclonal activation by anti-CD38
				or anti-RP105 antibodies (
				<xref rid="fig1" ref-type="fig">Fig. 1</xref>
				B). Addition of the general B cell survival factor IL-4 (
				<xref ref-type="bibr" rid="bib20">20</xref>
				) to the culture medium promotes B cell survival (
				<xref rid="fig1" ref-type="fig">Fig. 1</xref>
				C) and increases the fraction of dividing cells (
				<xref rid="fig1" ref-type="fig">Fig. 1</xref>
				B). These data suggest that accelerated death of
				PKC&#x003b2;-deficient B cells in vitro is likely causing defective
				proliferative responses of PKC&#x003b2;-deficient B cells to various
				stimuli in vitro.
			</p>
			<fig position="float" id="fig1">
				<label>Figure 1.</label>
				<caption>
					<p>
						Impaired survival and proliferation of PKC&#x003b2;-deficient B
						cells in vitro. (A) Accelerated cell death of PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						B cells cultured without stimulation. Percentage of cell viability
						of purified splenic B cells is plotted for wild-type (129/Sv)
						control (open circles) and PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						(filled circles) B cells. Each dot represents cells isolated from
						an individual mouse. (B) Impaired proliferative responses of
						PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						B cells in vitro in the absence of IL-4 survival signal. Purified
						splenic B cells of wild-type (left column) or PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						mice (right column) were labeled with CFSE and incubated for 3 d
						in the presence or absence of the indicated stimuli (see Materials
						and Methods for details). The thick line indicates the level of
						CFSE florescence in cells upon stimulation, whereas the thin line
						indicates the CFSE label of nonstimulated cells. Reduction in the
						CFSE fluorescence is proportional to the number of cell divisions.
						(C) IL-4 promotes survival of both wild-type and PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						B cells. FACS
						<sup>&#x000ae;</sup>
						analysis of Annexin-V in combination of 7AAD staining of wild-type
						(left column) and PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						(right column) B cells cultured in complete RPMI with or without
						IL-4. Note the increase of live cells annexin-V and 7AAD negative
						in the presence of IL-4. Numbers indicate percentages of gated
						cells.
					</p>
				</caption>
				<graphic xlink:href="020408f1"></graphic>
			</fig>
			<p>
				Poor survival of PKC&#x003b2;-deficient B cells in vitro correlates
				with their inability to up-regulate expression of the anti-apoptotic
				protein Bcl-xL upon stimulation with anti-IgM (
				<xref rid="fig2" ref-type="fig">Fig. 2</xref>
				) . Incubation of wild-type splenic B cells with anti-IgM results in
				progressive increase in the expression levels of the Bcl-xL (
				<xref rid="fig2" ref-type="fig">Fig. 2</xref>
				). Similar treatment of the PKC&#x003b2;-deficient B cells has a
				negative impact on the Bcl-xL expression level (
				<xref rid="fig2" ref-type="fig">Fig. 2</xref>
				). The inability of the surface expressed BCR to promote the
				expression of the anti-apoptotic Bcl-xL and Bcl-2 proteins likely
				causes the rapid death of the PKC&#x003b2;-deficient B cells.
			</p>
			<fig position="float" id="fig2">
				<label>Figure 2.</label>
				<caption>
					<p>
						Reduced expression of Bcl-xL and Bcl-2 after IgM cross-linking on
						B cells of PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						compared with control mice. Splenic B cells were isolated from
						PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						and PKC&#x003b2;
						<sup>+/+</sup>
						mice and incubated with 10 &#x003bc;g/ml anti-IgM for the
						indicated time (h). Bcl-xL and Bcl-2 protein expression was
						analyzed by Western blot analysis. Equal protein loading was
						controlled by anti-actin Western blotting. For quantification,
						band intensities were first normalized to the respective actin
						signal and then calculated as fold-change relative to unstimulated
						PKC&#x003b2;
						<sup>+/+</sup>
						, which was set to 1.0.
					</p>
				</caption>
				<graphic xlink:href="020408f2"></graphic>
			</fig>
			<p>
				Expression of Bcl-xL in B cells is dependent on the activity of the
				NF-&#x003ba;B transcription factor (
				<xref ref-type="bibr" rid="bib6">6</xref>
				,
				<xref ref-type="bibr" rid="bib21">21</xref>
				,
				<xref ref-type="bibr" rid="bib22">22</xref>
				), thus suggesting a possible involvement of PKC&#x003b2; in
				NF-&#x003ba;B regulation. Members of the NF-&#x003ba;B/Rel family of
				proteins include RelA, c-Rel, RelB p50/NF-&#x003ba;B1, and
				p52/NF-&#x003ba;B2 (
				<xref ref-type="bibr" rid="bib7">7</xref>
				). Deficiency in PKC&#x003b2; does not affect expression levels of
				RelA, c-Rel, and RelB in splenic B cells (
				<xref rid="fig3" ref-type="fig">Fig. 3</xref>
				A). NF-&#x003ba;B2 is synthesized as a large precursor (p100) that
				requires proteolytic processing to produce p52 (
				<xref ref-type="bibr" rid="bib7">7</xref>
				). The relative amount of unprocessed p100 NF-&#x003ba;B2 precursors
				is increased in PKC&#x003b2;-deficient B cells compared with control
				B cells (
				<xref rid="fig3" ref-type="fig">Fig. 3</xref>
				A).
			</p>
			<fig position="float" id="fig3">
				<label>Figure 3.</label>
				<caption>
					<p>
						Expression of Rel family proteins and
						IKK&#x003b1;/IKK&#x003b2;/IKK&#x003b3; complex in splenic B cells
						of PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						(&#x02212;/&#x02212;) and PKC&#x003b2;
						<sup>+/+</sup>
						(+/+) mice. (A) The amount of RelA, RelB, and c-Rel (left panel)
						as well as NF-&#x003ba;B2 (p100 and p52, right panel) were
						examined by sequential Western blotting. The actin blot (left
						panel, bottom) was used for quantification as described in
						<xref rid="fig2" ref-type="fig">Fig. 2</xref>
						. For NF-&#x003ba;B2 both p100 and p52 are quantified in relation
						to p52 of +/+ lysates. The asterisk (*) indicates a nonspecific
						band. (B) Normal composition of the
						IKK&#x003b1;/IKK&#x003b2;/IKK&#x003b3; signalosome complex in
						PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						B cells. CHAPS lysates of splenic B cells from PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						and PKC&#x003b2;
						<sup>+/+</sup>
						mice were immunoprecipitated with anti-IKK&#x003b1; antibody
						(IKK&#x003b1;) or control rabbit immunoglobulin (RIg). Whole cell
						lysates (WCL) are shown as blotting control. Membranes were
						sequentially probed with IKK&#x003b1; (top), IKK&#x003b2;
						(middle), and IKK&#x003b3; (bottom) antibodies.
					</p>
				</caption>
				<graphic xlink:href="020408f3a"></graphic>
				<graphic xlink:href="020408f3b"></graphic>
			</fig>
			<p>
				Defective NF-&#x003ba;B2 processing has been previously found in B
				cells deficient for IKK&#x003b1; or expressing a catalytically
				inactive form of IKK&#x003b1;, which is a component of the
				tri-member I&#x003ba;B kinase complex
				IKK&#x003b1;/IKK&#x003b2;/IKK&#x003b3; (
				<xref ref-type="bibr" rid="bib23">23</xref>
				). To test whether PKC&#x003b2; controls NF-&#x003ba;B2 processing
				through the regulation of IKK&#x003b1; expression or activation we
				have analyzed the expression and activation state of IKKs in
				PKC&#x003b2;-deficient splenic B cells. Both IKK&#x003b1; and
				IKK&#x003b2;, as well as the regulatory component of the I&#x003ba;B
				kinase complex, IKK&#x003b3;, are expressed in
				PKC&#x003b2;-deficient B cells at wild-type levels (
				<xref rid="fig3" ref-type="fig">Fig. 3</xref>
				B, WCL lanes). Immunoprecipitation of IKK&#x003b1; or IKK&#x003b2;
				from PKC&#x003b2;-deficient and control B cell lysates results in
				coprecipitation of IKK&#x003b2;/IKK&#x003b3; or
				IKK&#x003b1;/IKK&#x003b3;, respectively (
				<xref rid="fig3" ref-type="fig">Fig. 3</xref>
				B, and data not shown). These data suggest that expression of
				IKK&#x003b1; and formation of the I&#x003ba;B kinase complex is not
				controlled by PKC&#x003b2; in B cells.
			</p>
			<p>
				Activation of IKK&#x003b1; and IKK&#x003b2; is controlled by their
				phosphorylation in the activation loop of the kinase domain at
				serine residues 176/180 and 177/181, respectively (
				<xref ref-type="bibr" rid="bib24">24</xref>
				). Hence, the levels of phospho-IKK&#x003b1; (Ser-180) and
				phospho-IKK&#x003b2; (Ser-181) reflect indirectly the fraction of
				activated IKKs within a cell. In wild-type B cells more
				phospho-IKK&#x003b1; than phospho-IKK&#x003b2; can be detected.
				Incubation of the wild-type B cells with anti-IgM results in a
				drastic increase of the amount of phospho-IKK&#x003b2; while the
				phospho-IKK&#x003b1; levels remain relatively stable in the course
				of B cell stimulation (
				<xref rid="fig4" ref-type="fig">Fig. 4</xref>
				A, top panel). Deficiency in PKC&#x003b2; has a dramatic impact on
				the phosphorylation state of IKK&#x003b1; and to a lesser extent on
				IKK&#x003b2;. Phospho-IKK&#x003b1; is virtually absent both in
				nonstimulated and anti-IgM treated PKC&#x003b2;-deficient B cells (
				<xref rid="fig4" ref-type="fig">Fig. 4</xref>
				A, top panel). Moreover, the duration of IgM-mediated
				phosphorylation of IKK&#x003b2; is diminished in
				PKC&#x003b2;-deficient B cells compared with the wild-type B cells (
				<xref rid="fig4" ref-type="fig">Fig. 4</xref>
				A, top panel). Considering the essential role of serine
				phosphorylation in IKK&#x003b1; and IKK&#x003b2; activation, these
				results reveal PKC&#x003b2; as a key regulatory serine/threonine
				kinase connecting the BCR and IKK activation.
			</p>
			<fig position="float" id="fig4">
				<label>Figure 4.</label>
				<caption>
					<p>
						Impaired activation and NF-&#x003ba;B signaling in PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						B cells after BCR cross-linking. Absence of IKK&#x003b1;
						activation and shortened IKK&#x003b2; activation in PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						B cells. Splenic B cells of PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						and PKC&#x003b2;
						<sup>+/+</sup>
						mice were stimulated with 20 &#x003bc;g/ml of anti-IgM antibody
						(A, top panel) or 10 &#x003bc;g/ml anti-CD40 (B, top panel) for
						the indicated time (min). Western blot analysis of cytoplasmic
						extracts were done simultaneously with antibodies specific for
						phospho-Ser180 and phospho-Ser181 of IKK&#x003b1; and
						IKK&#x003b2;, respectively (top panel). The membrane was stripped
						and reprobed with antibodies recognizing nonphosphorylated
						IKK&#x003b1; and IKK&#x003b2;. For quantification, band
						intensities of the phosphorylation site&#x02013;specific blots
						were first normalized to the respective signal of unphosphorylated
						protein and then calculated as fold-change relative to
						unstimulated PKC&#x003b2;
						<sup>+/+</sup>
						, which was set to 1.0. Inefficient degradation and
						phosphorylation of I&#x003ba;B&#x003b1; after IgM cross-linking on
						PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						B cells (A, middle panel) and no alteration in IkBa
						phosphorylation and degradation after CD40 stimulation (B, middle
						panel). Splenic B cells were treated as in A. I&#x003ba;B&#x003b1;
						expression (top) and Ser32 phosphorylation (middle) were analyzed
						by Western blotting. Equal protein loading was controlled by
						anti-actin Western blotting (bottom). Quantification was done as
						in
						<xref rid="fig2" ref-type="fig">Fig. 2</xref>
						. Reduced DNA binding activity of NF-&#x003ba;B in PKC&#x003b2;
						<sup>&#x02212;/&#x02212;</sup>
						B cells after BCR cross-linking (A, bottom panel) and no
						alteration after CD40 stimulation (B, bottom panel). EMSA was
						performed with nuclear extracts of splenic B cells treated as in
						above. The specificity of NF-&#x003ba;B shift was confirmed by
						supershift with antibodies for p50, RelA, and c-Rel (Ab) and by
						using mutant oligonucleotides (m). For quantification, signal
						intensities were first normalized to the respective signal of an
						Oct-1 EMSA done with the same nuclear lysates and then calculated
						as fold-change relative to unstimulated PKC&#x003b2;
						<sup>+/+</sup>
						, which was set to 1.0.
					</p>
				</caption>
				<graphic xlink:href="020408f4a"></graphic>
				<graphic xlink:href="020408f4b"></graphic>
			</fig>
			<p>
				In wild-type B cells, the BCR-mediated activation of IKK&#x003b1; is
				followed by phosphorylation of I&#x003ba;B&#x003b1;. This in turn
				leads to I&#x003ba;B&#x003b1; degradation and translocation of the
				Rel proteins to the nucleus. Deficiency in PKC&#x003b2; and ensuing
				defective IKK&#x003b1; and IKK&#x003b2; phosphorylation result in
				impaired I&#x003ba;B&#x003b1; phosphorylation and degradation (
				<xref rid="fig4" ref-type="fig">Fig. 4</xref>
				A, middle panel). Congruently, activation of NF-&#x003ba;B is
				reduced in PKC&#x003b2;-deficient B cells (
				<xref rid="fig4" ref-type="fig">Fig. 4</xref>
				A, bottom panel).
			</p>
			<p>
				To test whether impaired NF-&#x003ba;B activation in
				PKC&#x003b2;-deficient B cells is specific for BCR-mediated signals,
				we tested stimulation of PKC&#x003b2;-deficient B cells through
				CD40, which in wild-type B cells also leads to NF-&#x003ba;B
				activation. The analysis of IKK&#x003b1; and IKK&#x003b2;
				phosphorylation in PKC&#x003b2;-deficient B cells stimulated through
				CD40 reveals a paucity in IKK&#x003b1; phosphorylaytion similar to
				that observed after BCR engagement (
				<xref rid="fig4" ref-type="fig">Fig. 4</xref>
				B, top panel). However, the CD40-mediated phosphorylation and
				degradation of I&#x003ba;B&#x003b1;, as well as the induction of
				NF-&#x003ba;B DNA-binding activity, are not impaired in
				PKC&#x003b2;-deficient B cells (
				<xref rid="fig4" ref-type="fig">Fig. 4</xref>
				B, middle and bottom panel). As a member of the TNF receptor family,
				CD40-mediated NF-&#x003ba;B activation is thought to require a
				different set of signaling molecules compared with BCR-mediated
				NF-&#x003ba;B activation, namely TRAF2, 3, 5, and 6 (
				<xref ref-type="bibr" rid="bib25">25</xref>
				). Possibly in CD40/TRAF-mediated NF-&#x003ba;B activation
				IKK&#x003b2; activation by itself is sufficient, or other kinases,
				like NIK, can substitute for IKK&#x003b1; (
				<xref ref-type="bibr" rid="bib26">26</xref>
				). In agreement with the normal induction of Rel family proteins
				CD40 stimulation alone improves the survival of
				PKC&#x003b2;-deficient B cells to wild-type levels (data not shown).
				This is also consistent with the finding that the CD40-mediated
				induction of anti-apoptotic A1 is not impaired in
				IKK&#x003b1;-deficient B cells (
				<xref ref-type="bibr" rid="bib27">27</xref>
				). In contrast to IgM stimulation, CD40-mediated proliferative
				responses are only mildly impaired in PKC&#x003b2;-deficient B cells
				(
				<xref ref-type="bibr" rid="bib13">13</xref>
				), which is also seen in IKK&#x003b1;-deficient B cells (
				<xref ref-type="bibr" rid="bib27">27</xref>
				). In conclusion, the PKC&#x003b2;-mediated regulation of
				NF-&#x003ba;B activation is largely specific for BCR-mediated
				signaling and has only a minor impact on CD40 mediated B cell
				activation.
			</p>
			<p>
				The pattern of defective NF-&#x003ba;B activation is very similar in
				B cells of PKC&#x003b2;-deficient and Xid mice (
				<xref ref-type="bibr" rid="bib9">9</xref>
				,
				<xref ref-type="bibr" rid="bib10">10</xref>
				). As PKC&#x003b2; can act as a negative regulator of Btk, the
				similar effect of both mutations on NF-&#x003ba;B activation appears
				paradoxical. However, increased or decreased Btk-mediated signaling
				may have the same outcome, as shown by the severe Xid-like phenotype
				of mice expressing a constitutively active Btk mutant (
				<xref ref-type="bibr" rid="bib28">28</xref>
				,
				<xref ref-type="bibr" rid="bib29">29</xref>
				). We think that in addition to its inhibitory role for Btk
				activation, PKC&#x003b2; may also act downstream of Btk to mediate
				the activation of IKKs. It remains to be seen whether PKC&#x003b2;
				regulates IKKs through direct phosphorylation. As the activation
				loop serine residues of IKK&#x003b1; or IKK&#x003b2; are not part of
				a PKC consensus phosphorylation site, other serine/threonine
				residues of IKK&#x003b1; and IKK&#x003b2; may serve as direct
				substrates for PKC&#x003b2;. Interestingly, a low stringency scan
				for common PKC phosphorylation sites returns several potential sites
				for IKK&#x003b1;, but none for IKK&#x003b2; (
				<xref ref-type="bibr" rid="bib30">30</xref>
				). Alternatively, PKC&#x003b2; may regulate IKKs indirectly through
				an intermediate kinase that would be directly controlled by
				PKC&#x003b2;. Regardless of the exact mechanism of the PKC&#x003b2;
				involvement in IKKs phosphorylation, the data presented reveal
				PKC&#x003b2; as a novel component of the NF-&#x003ba;B signaling
				axis responsible for the survival and activation of B cells after
				BCR cross-linking.
			</p>
		</sec>
	</body>
	<back>
		<ack>
			<p>We thank Michel Nussenzweig and Tsuneyasu Kaisho for the valuable
				discussion.</p>
			<p>This study was supported by grants from Systemic Lupus
				Erythematosus foundation (K. Saijo), The Rockefeller University's
				Women &#x00026; Science Fellowship Program (I.
				Mecklenbr&#x000e4;uker), The Rockefeller University Presidential
				Fellowship (C. Schmedt), National Institutes of Health (C. Schmedt,
				A. Santana, A. Tarakhovsky), and The Irene Diamond Fund (A.
				Tarakhovsky).</p>
		</ack>
		<ref-list>
			<ref id="bib1">
				<label>1</label>
				<citation citation-type="journal">
					Rajewsky, K.
					<year>1996</year>
					. Clonal selection and learning in the antibody system.
					<source>Nature.</source>
					<volume>381</volume>
					:
					<fpage>751</fpage>
					&#x02013;758.
					<pub-id pub-id-type="pmid">8657279</pub-id>
				</citation>
			</ref>
			<ref id="bib2">
				<label>2</label>
				<citation citation-type="journal">
					Fulcher, D.A., and A. Basten.
					<year>1997</year>
					. B cell life span: a review.
					<source>Immunol. Cell Biol.</source>
					<volume>75</volume>
					:
					<fpage>446</fpage>
					&#x02013;455.
					<pub-id pub-id-type="pmid">9429891</pub-id>
				</citation>
			</ref>
			<ref id="bib3">
				<label>3</label>
				<citation citation-type="journal">
					Conley, M.E., and M.D. Cooper.
					<year>1998</year>
					. Genetic basis of abnormal B cell development.
					<source>Curr. Opin. Immunol.</source>
					<volume>10</volume>
					:
					<fpage>399</fpage>
					&#x02013;406.
					<pub-id pub-id-type="pmid">9722915</pub-id>
				</citation>
			</ref>
			<ref id="bib4">
				<label>4</label>
				<citation citation-type="journal">
					Satterthwaite, A., and O. Witte.
					<year>1996</year>
					. Genetic analysis of tyrosine kinase function in B cell
					development.
					<source>Annu. Rev. Immunol.</source>
					<volume>14</volume>
					:
					<fpage>131</fpage>
					&#x02013;154.
					<pub-id pub-id-type="pmid">8717510</pub-id>
				</citation>
			</ref>
			<ref id="bib5">
				<label>5</label>
				<citation citation-type="journal">
					Lam, K.P., R. Kuhn, and K. Rajewsky.
					<year>1997</year>
					. In vivo ablation of surface immunoglobulin on mature B cells by
					inducible gene targeting results in rapid cell death.
					<source>Cell.</source>
					<volume>90</volume>
					:
					<fpage>1073</fpage>
					&#x02013;1083.
					<pub-id pub-id-type="pmid">9323135</pub-id>
				</citation>
			</ref>
			<ref id="bib6">
				<label>6</label>
				<citation citation-type="journal">
					Karin, M., and A. Lin.
					<year>2002</year>
					. NF-&#x003ba;B at the crossroads of life and death.
					<source>Nat. Immunol.</source>
					<volume>3</volume>
					:
					<fpage>221</fpage>
					&#x02013;227.
					<pub-id pub-id-type="pmid">11875461</pub-id>
				</citation>
			</ref>
			<ref id="bib7">
				<label>7</label>
				<citation citation-type="journal">
					Karin, M., and Y. Ben-Neriah.
					<year>2000</year>
					. Phosphorylation meets ubiquitination: the control of
					NF-&#x003ba;B activity.
					<source>Annu. Rev. Immunol.</source>
					<volume>18</volume>
					:
					<fpage>621</fpage>
					&#x02013;663.
					<pub-id pub-id-type="pmid">10837071</pub-id>
				</citation>
			</ref>
			<ref id="bib8">
				<label>8</label>
				<citation citation-type="journal">
					Silverman, N., and T. Maniatis.
					<year>2001</year>
					. NF-&#x003ba;B signaling pathways in mammalian and insect innate
					immunity.
					<source>Genes Dev.</source>
					<volume>15</volume>
					:
					<fpage>2321</fpage>
					&#x02013;2342.
					<pub-id pub-id-type="pmid">11562344</pub-id>
				</citation>
			</ref>
			<ref id="bib9">
				<label>9</label>
				<citation citation-type="journal">
					Petro, J.B., S.M. Rahman, D.W. Ballard, and W.N. Khan.
					<year>2000</year>
					. Bruton's tyrosine kinase is required for activation of
					I&#x003ba;B kinase and nuclear factor &#x003ba;B in response to B
					cell receptor engagement.
					<source>J. Exp. Med.</source>
					<volume>191</volume>
					:
					<fpage>1745</fpage>
					&#x02013;1754.
					<pub-id pub-id-type="pmid">10811867</pub-id>
				</citation>
			</ref>
			<ref id="bib10">
				<label>10</label>
				<citation citation-type="journal">
					Bajpai, U.D., K. Zhang, M. Teutsch, R. Sen, and H.H. Wortis.
					<year>2000</year>
					. Bruton's tyrosine kinase links the B cell receptor to nuclear
					factor &#x003ba;B activation.
					<source>J. Exp. Med.</source>
					<volume>191</volume>
					:
					<fpage>1735</fpage>
					&#x02013;1744.
					<pub-id pub-id-type="pmid">10811866</pub-id>
				</citation>
			</ref>
			<ref id="bib11">
				<label>11</label>
				<citation citation-type="journal">
					Khan, W.N.
					<year>2001</year>
					. Regulation of B lymphocyte development and activation by Bruton's
					tyrosine kinase.
					<source>Immunol. Res.</source>
					<volume>23</volume>
					:
					<fpage>147</fpage>
					&#x02013;156.
					<pub-id pub-id-type="pmid">11444380</pub-id>
				</citation>
			</ref>
			<ref id="bib12">
				<label>12</label>
				<citation citation-type="journal">
					Anderson, J.S., M. Teutsch, Z. Dong, and H.H. Wortis.
					<year>1996</year>
					. An essential role for Bruton's tyrosine kinase in the regulation
					of B-cell apoptosis.
					<source>Proc. Natl. Acad. Sci. USA.</source>
					<volume>93</volume>
					:
					<fpage>10966</fpage>
					&#x02013;10971.
					<pub-id pub-id-type="pmid">8855292</pub-id>
				</citation>
			</ref>
			<ref id="bib13">
				<label>13</label>
				<citation citation-type="journal">
					Leitges, M., C. Schmedt, R. Guinamard, J. Davoust, S. Schaal, S.
					Stabel, and A. Tarakhovsky.
					<year>1996</year>
					. Immunodeficiency in protein kinase Cbeta-deficient mice.
					<source>Science.</source>
					<volume>273</volume>
					:
					<fpage>788</fpage>
					&#x02013;791.
					<pub-id pub-id-type="pmid">8670417</pub-id>
				</citation>
			</ref>
			<ref id="bib14">
				<label>14</label>
				<citation citation-type="journal">
					Chan, V.W., I. Mecklenbrauker, I. Su, G. Texido, M. Leitges, R.
					Carsetti, C.A. Lowell, K. Rajewsky, K. Miyake, and A. Tarakhovsky.
					<year>1998</year>
					. The molecular mechanism of B cell activation by toll-like
					receptor protein RP-105.
					<source>J. Exp. Med.</source>
					<volume>188</volume>
					:
					<fpage>93</fpage>
					&#x02013;101.
					<pub-id pub-id-type="pmid">9653087</pub-id>
				</citation>
			</ref>
			<ref id="bib15">
				<label>15</label>
				<citation citation-type="journal">
					Kang, S.W., M.I. Wahl, J. Chu, J. Kitaura, Y. Kawakami, R.M. Kato,
					R. Tabuchi, A. Tarakhovsky, T. Kawakami, C.W. Turck, et al.
					<year>2001</year>
					. PKCbeta modulates antigen receptor signaling via regulation of
					Btk membrane localization.
					<source>EMBO J.</source>
					<volume>20</volume>
					:
					<fpage>5692</fpage>
					&#x02013;5702.
					<pub-id pub-id-type="pmid">11598012</pub-id>
				</citation>
			</ref>
			<ref id="bib16">
				<label>16</label>
				<citation citation-type="journal">
					Texido, G., I.H. Su, I. Mecklenbrauker, K. Saijo, S.N. Malek, S.
					Desiderio, K. Rajewsky, and A. Tarakhovsky.
					<year>2000</year>
					. The B-cell-specific Src-family kinase Blk is dispensable for
					B-cell development and activation.
					<source>Mol. Cell. Biol.</source>
					<volume>20</volume>
					:
					<fpage>1227</fpage>
					&#x02013;1233.
					<pub-id pub-id-type="pmid">10648608</pub-id>
				</citation>
			</ref>
			<ref id="bib17">
				<label>17</label>
				<citation citation-type="journal">
					Yamashita, Y., K. Miyake, Y. Kikuchi, K. Takatsu, S. Noda, A.
					Kosugi, and M. Kimoto.
					<year>1995</year>
					. A monoclonal antibody against a murine CD38 homologue delivers a
					signal to B cells for prolongation of survival and protection
					against apoptosis in vitro: unresponsiveness of X-linked
					immunodeficient B cells.
					<source>Immunology.</source>
					<volume>85</volume>
					:
					<fpage>248</fpage>
					&#x02013;255.
					<pub-id pub-id-type="pmid">7642213</pub-id>
				</citation>
			</ref>
			<ref id="bib18">
				<label>18</label>
				<citation citation-type="journal">
					Miyake, K., Y. Yamashita, M. Ogata, T. Sudo, and M. Kimoto.
					<year>1995</year>
					. RP105, a novel B cell surface molecule implicated in B cell
					activation, is a member of the leucine-rich repeat protein family.
					<source>J. Immunol.</source>
					<volume>154</volume>
					:
					<fpage>3333</fpage>
					&#x02013;3340.
					<pub-id pub-id-type="pmid">7897216</pub-id>
				</citation>
			</ref>
			<ref id="bib19">
				<label>19</label>
				<citation citation-type="journal">
					Meclenbr&#x000e4;uker, I., K. Saijo, N.Y. Zheng, M. Leitges, and A.
					Tarakhovsky.
					<year>2002</year>
					. Protein kinase C&#x003b4; controls self-antigen&#x02013;induced
					B-cell tolerance.
					<source>Nature</source>
					.
					<volume>416</volume>
					:
					<fpage>860</fpage>
					&#x02013;865.
					<pub-id pub-id-type="pmid">11976686</pub-id>
				</citation>
			</ref>
			<ref id="bib20">
				<label>20</label>
				<citation citation-type="journal">
					Mori, M., S.C. Morris, T. Orekhova, M. Marinaro, E. Giannini, and
					F.D. Finkelman.
					<year>2000</year>
					. IL-4 promotes the migration of circulating B cells to the spleen
					and increases splenic B cell survival.
					<source>J. Immunol.</source>
					<volume>164</volume>
					:
					<fpage>5704</fpage>
					&#x02013;5712.
					<pub-id pub-id-type="pmid">10820247</pub-id>
				</citation>
			</ref>
			<ref id="bib21">
				<label>21</label>
				<citation citation-type="journal">
					Baichwal, V.R., and P.A. Baeuerle.
					<year>1997</year>
					. Activate NF-kappa B or die?
					<source>Curr. Biol.</source>
					<volume>7</volume>
					:
					<fpage>R94</fpage>
					&#x02013;R96.
					<pub-id pub-id-type="pmid">9081673</pub-id>
				</citation>
			</ref>
			<ref id="bib22">
				<label>22</label>
				<citation citation-type="journal">
					Wu, M., H. Lee, R.E. Bellas, S.L. Schauer, M. Arsura, D. Katz, M.J.
					FitzGerald, T.L. Rothstein, D.H. Sherr, and G.E. Sonenshein.
					<year>1996</year>
					. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells.
					<source>EMBO J.</source>
					<volume>15</volume>
					:
					<fpage>4682</fpage>
					&#x02013;4690.
					<pub-id pub-id-type="pmid">8887559</pub-id>
				</citation>
			</ref>
			<ref id="bib23">
				<label>23</label>
				<citation citation-type="journal">
					Senftleben, U., Y. Cao, G. Xiao, F.R. Greten, G. Krahn, G. Bonizzi,
					Y. Chen, Y. Hu, A. Fong, S.C. Sun, and M. Karin.
					<year>2001</year>
					. Activation by IKK&#x003b1; of a second, evolutionary conserved,
					NF-&#x003ba; B signaling pathway.
					<source>Science.</source>
					<volume>293</volume>
					:
					<fpage>1495</fpage>
					&#x02013;1499.
					<pub-id pub-id-type="pmid">11520989</pub-id>
				</citation>
			</ref>
			<ref id="bib24">
				<label>24</label>
				<citation citation-type="journal">
					Delhase, M., M. Hayakawa, Y. Chen, and M. Karin.
					<year>1999</year>
					. Positive and negative regulation of I&#x003ba;B kinase activity
					through IKK&#x003b2; subunit phosphorylation.
					<source>Science.</source>
					<volume>284</volume>
					:
					<fpage>309</fpage>
					&#x02013;313.
					<pub-id pub-id-type="pmid">10195894</pub-id>
				</citation>
			</ref>
			<ref id="bib25">
				<label>25</label>
				<citation citation-type="journal">
					Arch, R.H., R.W. Gedrich, and C.B. Thompson.
					<year>1998</year>
					. Tumor necrosis factor receptor-associated factors
					(TRAFs)&#x02014;a family of adapter proteins that regulates life
					and death.
					<source>Genes Dev.</source>
					<volume>12</volume>
					:
					<fpage>2821</fpage>
					&#x02013;2830.
					<pub-id pub-id-type="pmid">9744859</pub-id>
				</citation>
			</ref>
			<ref id="bib26">
				<label>26</label>
				<citation citation-type="journal">
					Garceau, N., Y. Kosaka, S. Masters, J. Hambor, R. Shinkura, T.
					Honjo, and R.J. Noelle.
					<year>2000</year>
					. Lineage-restricted function of nuclear factor &#x003ba;B-inducing
					kinase (NIK) in transducing signals via CD40.
					<source>J. Exp. Med.</source>
					<volume>191</volume>
					:
					<fpage>381</fpage>
					&#x02013;386.
					<pub-id pub-id-type="pmid">10637282</pub-id>
				</citation>
			</ref>
			<ref id="bib27">
				<label>27</label>
				<citation citation-type="journal">
					Kaisho, T., K. Takeda, T. Tsujimura, T. Kawai, F. Nomura, N.
					Terada, and S. Akira.
					<year>2001</year>
					. I&#x003ba;B kinase &#x003b1; is essential for mature B cell
					development and function.
					<source>J. Exp. Med.</source>
					<volume>193</volume>
					:
					<fpage>417</fpage>
					&#x02013;426.
					<pub-id pub-id-type="pmid">11181694</pub-id>
				</citation>
			</ref>
			<ref id="bib28">
				<label>28</label>
				<citation citation-type="journal">
					Dingjan, G.M., A. Maas, M.C. Nawijn, L. Smit, J.S. Voerman, F.
					Grosveld, and R.W. Hendriks.
					<year>1998</year>
					. Severe B cell deficiency and disrupted splenic architecture in
					transgenic mice expressing the E41K mutated form of Bruton's
					tyrosine kinase.
					<source>EMBO J.</source>
					<volume>17</volume>
					:
					<fpage>5309</fpage>
					&#x02013;5320.
					<pub-id pub-id-type="pmid">9736610</pub-id>
				</citation>
			</ref>
			<ref id="bib29">
				<label>29</label>
				<citation citation-type="journal">
					Maas, A., G.M. Dingjan, F. Grosveld, and R.W. Hendriks.
					<year>1999</year>
					. Early arrest in B cell development in transgenic mice that
					express the E41K Bruton's tyrosine kinase mutant under the control
					of the CD19 promoter region.
					<source>J. Immunol.</source>
					<volume>162</volume>
					:
					<fpage>6526</fpage>
					&#x02013;6533.
					<pub-id pub-id-type="pmid">10352268</pub-id>
				</citation>
			</ref>
			<ref id="bib30">
				<label>30</label>
				<citation citation-type="journal">
					Yaffe, M.B., G.G. Leparc, J. Lai, T. Obata, S. Volinia, and L.C.
					Cantley.
					<year>2001</year>
					. A motif-based profile scanning approach for genome-wide
					prediction of signaling pathways.
					<source>Nat. Biotechnol.</source>
					<volume>19</volume>
					:
					<fpage>348</fpage>
					&#x02013;353.
					<pub-id pub-id-type="pmid">11283593</pub-id>
				</citation>
			</ref>
		</ref-list>
	</back>
</article>


